At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 290 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue
In Brief
A Phase 4 clinical trial evaluating Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 290 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartAug 2015
Primary CompletionFeb 2018
TodayJul 2026
First PostedApr 17, 2015
Enrollment StartAug 7, 2015
Primary CompletionFeb 27, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.2 years ago
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspensiondrug
Brinz/brim vehicledrug
Inactive ingredients used as a placebo for masking purposes
Prostaglandin analoguedrug